Latest Avastin Stories
U.S. researchers say the drug Avastin may improve the survival rates for recurrent glioblastomas -- the most aggressive type of primary brain tumor. Senior author Dr.
The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.
UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will shrink when treated by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.
UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment.
The mixture of two anti-cancer medications, along with chemotherapy, can gradually halt advanced non-small cell lung cancer, says a new study released on Saturday.
The U.S. Food and Drug Administration has approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme -- a form of brain cancer. GBM is a rapidly progressing cancer that invades brain tissue and can impact physical activities and mental abilities, the FDA said.
The drug Avastin fell short in a clinical trial of its goal to reduce the recurrence of early-stage colon cancer, U.S.
Sutent/Taxol Will Earn Decision Resources' Clinical Gold Standard Status for the Indication by 2012, According to a New Report from Decision Resources WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in metastatic triple-negative breast cancer.
Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just under $250 million in 2007 to more than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's...
- A trick or prank.